Defining outcomes for beta cell replacement therapy: a work in progress

Area of Science:

• Endocrinology and Metabolism
• Transplantation Immunology
• Regenerative Medicine

Background:

• Beta cell replacement therapy, including pancreas and islet transplantation, offers a potential cure for diabetes.
• Clinical progress has been hindered by a lack of standardized outcome definitions and glycaemic control metrics.
• Existing metrics lack alignment with advancements in artificial insulin delivery and artificial pancreas technologies.

Purpose of the Study:

• To establish a consensus on the definition of function and failure for beta cell replacement therapies.
• To provide clear, consistently applied glycaemic control metrics for evaluating treatment efficacy.
• To bridge the gap between transplantation outcomes and artificial pancreas development.

Main Methods:

• Collaborative effort between the International Pancreas & Islet Transplant Association (IPITA) and the European Pancreas and Islet Transplant Association (EPITA).
• Development of a joint statement through consensus-building discussions.
• Review and synthesis of existing literature and clinical practices.

Main Results:

• A unified set of definitions for beta cell replacement therapy outcomes has been proposed.
• Standardized glycaemic control metrics are recommended for consistent evaluation.
• The consensus aims to improve the comparability and reliability of transplant outcomes.

Conclusions:

• Defined outcomes are critical for the clinical acceptance and advancement of beta cell replacement therapies.
• Standardization will facilitate progress in diabetes management through transplantation.
• This joint statement provides a foundational framework for future research and clinical guidelines.